• Users Online: 218
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2020  |  Volume : 3  |  Issue : 3  |  Page : 124-127

Seroprevalence of SARS-CoV-2-specific neutralizing antibodies in COVID-19 pneumonia patients


1 Department of Respiratory Medicine, Apollo Main Hospitals, Chennai, Tamil Nadu, India
2 Department of Respiratory Medicine, Sundaram Medical Foundation Hospitals, Chennai, Tamil Nadu, India

Correspondence Address:
Sivanthi Sapna Rajendran
Department of Respiratory Medicine, Apollo Hospitals, Greams Road, Chennai, Tamil Nadu
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/japt.japt_11_21

Rights and Permissions

Aim: The aim is to know the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific neutralizing antibody responses in COVID-19 pneumonia patients and correlation of antibody titer values with COVID-19 pneumonia Category, cyclic threshold values of COVID-19 reverse transcription polymerase chain reaction (RT-PCR) test, and computed tomography (CT) chest severity score. Material and Methods: Using serologic assay, SARS-CoV-2 antibody titers were measured in 65 patients with COVID-19 pneumonia symptoms with either positive or negative COVID-19 RT-PCR tests and radiological changes in CT chest during COVID-19 Pandemic period. About 3–5 ml of venous blood was collected and blood samples were tested using Abbott SARS-COV 2 immunoglobulin G (IgG) assay. This assay detects IgG Antibody against SARS-CoV-2 nucleocapsid protein and has a sensitivity of 100% and a specificity of 99.6%. Sixty-five patients were enrolled for this study and their clinical data, comorbid conditions, laboratory RT-PCR test reports, SARS-COV-2 antibody titers, and CT chest severity score were assessed cross-sectionally. Results: The study was done on 65 hospitalized patients. Among them, 39 were male (60.9%) and 25 were female (39.1%). Most common comorbidities among them were systemic hypertension (16.7%), chronic obstructive pulmonary disease (36.1%), diabetes mellitus (5.6%), coronary artery disease (22.2%), and bronchial asthma (27.8%). Among 65 patients, 36 (56.3%) tested COVID-19 RT-PCR positive and 28 (43.8%) tested COVID-19 RT-PCR negative. 24 patients belong to category B1 (55.8%), 11 patients belong to category B2 (25.6%), and 8 patients belong to category C (18.6%). A high seroprevalence of SARS-CoV-2 IgG antibody after 2 weeks were observed-17% among Category B1 patients, 26% among Category B2 patients, and 43% among category C patients. CT chest severity score was correlated with serum antibody titers by Pearson correlation which revealed a positive correlation that is statistically significant (0.01). Cycle Threshold value of COVID-19 RT-PCR reports was correlated with serum antibody titers by Pearson correlation which revealed a negative correlation that is statistically insignificant. Conclusion: This study found a high seroprevalence of SARS-CoV-2 specific IgG antibodies among COVID-19 pneumonia patients and positive correlation of antibody titers with clinical COVID-19 pneumonia category and with CT Chest Severity score.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed350    
    Printed4    
    Emailed0    
    PDF Downloaded19    
    Comments [Add]    

Recommend this journal